Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial-Reference-Cited by-同舟云学术

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

Published:2006-02-24 Issue:2 Volume:24 Page:151-158
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Sawa Toshiyuki,Yana Takashi,Takada Minoru,Sugiura Takahiko,Kudoh Shinzoh,Kamei Tadashi,Isobe Takeshi,Yamamoto Hidehiko,Yokota Soichiro,Katakami Nobuyuki,Tohda Yuji,Kawakami Akira,Nakanishi Yoichi,Ariyoshi Yutaka

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-006-5937-2.pdf

Reference24 articles.

1. Ishizumi K, Ohashi N, Tanno N (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52:4477–4485

2. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067–1073

3. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80:69–76

4. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89:1055–1060

5. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M (1989) Toxicological aspects of a novel 9-aminoanthracyline, SM-5887. Jpn J Cancer Res 80:77–82

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320);Investigational New Drugs;2020-11-07

2. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia;Respiratory Investigation;2019-11

3. Antineoplastic-related cardiovascular toxicity: A systematic review and meta-analysis in Asia;Critical Reviews in Oncology/Hematology;2019-09

4. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer;Annals of Oncology;2017-02

5. Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study;Japanese Journal of Clinical Oncology;2016-05-09